Patents by Inventor Nuria Diaz Buezo

Nuria Diaz Buezo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 6-METHOXY-3,4-DIHYDRO-1H-ISOQUINOLIN COMPOUNDS
    Publication number: 20230373927
    Abstract: In an embodiment, the present invention provides a compound of the formula: wherein R1 is selected from the group consisting of F and H; R2 is selected from the group consisting of CH3, CH3CHCH3 and —NHCH2CH(CH3)2; R3 is selected from the group consisting of H and —CH2OCH3; R4 is selected from the group consisting of H and CH3; R5 is selected from the group consisting of H and CH3; R6 is selected from the group consisting of H and OH; R7 is selected from the group consisting of or a pharmaceutically acceptable salt thereof, and methods of using this compound for positive allosteric modulation of a receptor selected from the group consisting of GLP1, GIP, and glucagon.
    Type: Application
    Filed: October 6, 2021
    Publication date: November 23, 2023
    Inventors: Ana Belén BUENO MELENDO, Jayana Pankajkumar LINESWALA, Gema RUANO PLAZA, Nuria Diaz BUEZO
  • PYRROLIDINE COMPOUNDS
    Publication number: 20220169636
    Abstract: The present invention provides compounds of the Formula or a pharmaceutically acceptable salt thereof, and compounds processes for preparing the compounds and their salts, and a pharmaceutical composition.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 2, 2022
    Inventors: Celia Lafuente BLANCO, Nuria Diaz BUEZO, Jose Antonio Martinez PEREZ, Gema Consuelo SANZ GIL, Julian Priego SOLER
  • Pyrrolidine compounds
    Patent number: 11286249
    Abstract: The present invention provides compounds of the Formula wherein L is selected from the group consisting of —CH2NHCH2—, —CH2NH—, —NH—, —S—, —S(O)—, —S(O)2—, —O—, —OCH2—, —OCH2CH2O—, —NHSO2NH—, or a pharmaceutically acceptable salt thereof; a compound of the formula: processes for preparing the compounds and their salts, a pharmaceutical composition, and methods of treating patients in need of such treatment.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: March 29, 2022
    Assignee: Eli Lilly and Company
    Inventors: Celia Lafuente Blanco, Nuria Diaz Buezo, Jose Antonio Martinez Perez, Gema Consuelo Sanz Gil, Julian Priego Soler
  • PYRROLIDINE COMPOUNDS
    Publication number: 20210253559
    Abstract: The present invention provides compounds of the Formula wherein L is selected from the group consisting of —CH2NHCH2—, —CH2NH—, —NH—, —S—, —S(O)—, —S(O)2—, —O—, —OCH2—, —OCH2CH2O—, —NHSO2NH—, or a pharmaceutically acceptable salt thereof; a compound of the formula: processes for preparing the compounds and their salts, a pharmaceutical composition, and methods of treating patients in need of such treatment.
    Type: Application
    Filed: June 3, 2020
    Publication date: August 19, 2021
    Inventors: Celia Lafuente BLANCO, Nuria Diaz BUEZO, Jose Antonio Martinez PEREZ, Gema Consuelo SANZ GIL, Julian Priego SOLER
  • Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors
    Patent number: 9416138
    Abstract: The present invention provides compounds of Formula I. Wherein R1, L, and A are as described herein, or a pharmaceutical salt thereof, processes for preparing the compounds, and methods of treating a condition, such as hypertriglyceridemia, using the compounds.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: August 16, 2016
    Assignee: Eli Lilly and Company
    Inventors: Francisco Javier Agejas-Chicharro, Nuria Diaz Buezo, Joseph Michael Gruber, Douglas Richard Stack
  • NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS
    Publication number: 20150284404
    Abstract: The present invention provides compounds of Formula I. Wherein R1, L, and A are as described herein, or a pharmaceutical salt thereof, processes for preparing the compounds, and methods of treating a condition, such as hypertriglyceridemia, using the compounds.
    Type: Application
    Filed: October 30, 2013
    Publication date: October 8, 2015
    Inventors: Francisco Javier Agejas-Chicharro, Nuria Diaz Buezo, Joseph Michael Gruber, Douglas Richard Stack
  • SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS
    Publication number: 20120214784
    Abstract: An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal models that the compounds of the present invention are useful for the treatment of migraines.
    Type: Application
    Filed: November 12, 2010
    Publication date: August 23, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Ana Belen Benito Collado, Nuria Diaz Buezo, Alma Maria Jimenez-Aguado, Celia Lafuente Blanco, Maria Angeles Martinez-Grau, Concepcion Pedregal Tercero, Miguel Angel Toledo Escribano
  • Spiropiperidine compounds as ORL-1 receptor antagonists
    Patent number: 8232289
    Abstract: An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: July 31, 2012
    Assignee: Eli Lilly and Company
    Inventors: Ana Belen Benito Collado, Nuria Diaz Buezo, Alma Maria Jimenez-Aguado, Celia Lafuente Blanco, Maria Angeles Martinez-Grau, Concepcion Pedregal-Tercero, Miguel Angel Toledo Escribano
  • Kappa selective opioid receptor antagonist
    Patent number: 8173695
    Abstract: A selective kappa opioid receptor antagonist useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: May 8, 2012
    Assignee: Eli Lilly and Company
    Inventors: Nuria Diaz Buezo, David Lee McKinzie, Charles Howard Mitch, Concepcion Pedregal-Tercero
  • SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS
    Publication number: 20110118251
    Abstract: An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Application
    Filed: November 10, 2010
    Publication date: May 19, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Ana Belen BENITO COLLADO, Nuria DIAZ BUEZO, Alma Maria JIMENEZ-AGUADO, Celia LAFUENTE BLANCO, Maria Angeles MARTINEZ-GRAU, Concepcion PEDREGAL-TERCERO, Miguel Angel TOLEDO ESCRIBANO
  • KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST
    Publication number: 20100197669
    Abstract: A selective kappa opioid receptor antagonist useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions.
    Type: Application
    Filed: April 9, 2010
    Publication date: August 5, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Nuria DIAZ BUEZO, Concepcion PEDREGAL-TERCERO, David Lee MCKINZIE, Charles Howard Mitch
  • Kappa selective opioid receptor antagonist
    Patent number: 7709522
    Abstract: A selective kappa opioid receptor antagonist, (S)-3-Fluoro-4-[4-[2-(3,5-dimethylphenyl)pyrrolidin-1-yl-methyl]phenoxy]benzamide or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, and anxiety and/or depression, or schizophrenia as independent comorbid conditions.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: May 4, 2010
    Assignee: Eli Lilly and Company
    Inventors: Nuria Diaz Buezo, Concepcion Pedregal-Tercero, David Lee McKinzie, Charles Howard Mitch
  • KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST
    Publication number: 20090186873
    Abstract: A selective kappa opioid receptor antagonist useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions.
    Type: Application
    Filed: January 13, 2009
    Publication date: July 23, 2009
    Inventors: Nuria Diaz Buezo, Concepcion Pedregal-Tercero, David Lee McKinzie, Charles Howard Mitch
  • DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20080269296
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z. A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: March 21, 2008
    Publication date: October 30, 2008
    Inventors: Maria-Jesus Blanco-Pillado, Mark Donald Chappell, Marta Garcia De La Torre, Nuria Diaz Buezo, James Erwin Fritz, William Glen Holloway, James Edward Matt, Charles Howard Mitch, Concepcion Pedregal-Tercero, Steven James Quimby, Miles Goodman Siegel, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi, Elizabeth Marie Thomas, Chad Nolan Wolfe
  • DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20080255152
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: March 21, 2008
    Publication date: October 16, 2008
    Inventors: Maria-Jesus Blanco-Pillado, Mark Donald Chappell, Marta Garcia De La Torre, Nuria Diaz Buezo, James Erwin Fritz, William Glen Holloway, James Edward Matt, Charies Howard Mitch, Concepcion Pedregal-Tercero, Steven James Quimby, Miles Goodman Siegel, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi, Elizabeth Marie Thomas, Chad Nolan Wolfe
  • Opioid receptor antagonists
    Patent number: 7414132
    Abstract: A compound of the formula (I); wherein the variables X1 to X10, R1 to R7 including R3?, E, W, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: August 19, 2008
    Assignee: Eli Lilly and Company
    Inventors: Marta Garcia De La Torre, Nuria Diaz Buezo, Prabhakar Kondaji Jadhav, Charles Howard Mitch, Concepcion Pedregal-Tercero
  • Diaryl ethers as opioid receptor antagonist
    Patent number: 7381719
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: June 3, 2008
    Assignee: Eli Lilly and Company
    Inventors: Maria-Jesus Blanco-Pillado, Marta Garcia De La Torre, Nuria Diaz Buezo, William Glen Holloway, James Edward Matt, Charles Howard Mitch, Concepcion Pedregal-Tercero, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi
  • Opioid receptor antagonists
    Patent number: 7288543
    Abstract: A compound of the formula (I) (I) wherein the variables X1 to X6, Ra, Rb, R1 to R7 including R3?, E, p, j, y, z, A, B and C are as described or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed
    Type: Grant
    Filed: March 8, 2005
    Date of Patent: October 30, 2007
    Assignee: Eli Lilly and Company
    Inventors: Howard Barff Broughton, Nuria Diaz Buezo, Charles Howard Mitch, Concepcion Pedregal-Tercero
  • Opioid receptor antagonists
    Publication number: 20070179129
    Abstract: A compound of the formula (I) (I) wherein the variables X1 to X6, Ra, Rb, R1 to R7 including R3?, E, p, j, y, z, A, B and C are as described or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: March 8, 2005
    Publication date: August 2, 2007
    Inventors: Howard Broughton, Nuria Diaz Buezo, Charles Mitch, Concepcion Pedregal-Tercero
  • Opioid receptor antagonists
    Publication number: 20070112036
    Abstract: A compound of the formula (I); wherein the variables X1 to X10, R1 to R7 including R3?, E, W, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: December 15, 2004
    Publication date: May 17, 2007
    Applicant: ELI LILLY AND COMPANY
    Inventors: Marta De La Torre, Nuria Diaz Buezo, Prabhakar Jadhav, Charles Mitch, Concepcion Pedregal-Tercero